.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
Colorcon
Federal Trade Commission
Covington
Cantor Fitzgerald
McKinsey
Farmers Insurance
Julphar
Chubb

Generated: July 20, 2017

DrugPatentWatch Database Preview

PHOTREXA Drug Profile

« Back to Dashboard

Which patents cover Photrexa, and what generic Photrexa alternatives are available?

Photrexa is a drug marketed by Avedro Inc and is included in one NDA.

The generic ingredient in PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

Summary for Tradename: PHOTREXA

You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM') AND hsdb_drugname IS NOT NULL' at line 1
Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list26
Clinical Trials: see list1
Patent Applications: see list2,375